Narcolepsy Without Cataplexy
12
2
2
8
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 12 trials
100.0%
+13.5% vs benchmark
8%
1 trials in Phase 3/4
63%
5 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (12)
Decreasing Nightmares in Adults With Narcolepsy
Narcolepsy Nightmare Study
Clarithromycin Mechanisms in Hypersomnia Syndromes
Efficacy and Safety of Pitolisant in Pediatric Narcoleptic Patients With or Without Cataplexy, Double-blind Study Followed by a Prolonged Open-label Period
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Awareness and Self-Compassion Enhancing Narcolepsy Treatment
Modafinil Versus Amphetamines for the Treatment of Narcolepsy Type 2 and Idiopathic Hypersomnia
An Open Label Study of NLS-2 (Mazindol Extended Release) in Subjects With Narcolepsy
'A Profile of Physical Performance Variables in an Out-patient Adult Population With Narcolepsy'
Expanded Access Program to Provide Treatment With Pitolisant to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy
A Study of Safety and Efficacy of BTD-001 in Treatment of Patients With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2
Flumazenil for the Treatment of Primary Hypersomnia